Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Oral Elacestrant vs. Standard-of-Care in ER+/HER2- Advanced or mBC Without Detectable ESR1 Mutation (EMERALD) - Subgroup Analysis by Prior Duration of CDK4/6i + ET"

102 views
June 7, 2023
0 Comments
Login to view comments. Click here to Login
Breast